gnf6702 gnf6702 gnf6702 is the name for a broad-spectrum antiprotozoal drug invented by researchers working at the genomics institute of the novartis research foundation in 2013, with activity against leishmaniasis, chagas disease and sleeping sickness. these three diseases are caused by related kinetoplastid parasites, which share similar biology. gnf6702 acts as allosteric proteasome inhibitor which was effective against infection with any of the three protozoal diseases in mice, while having little evident toxicity to mammalian cells. gnf6702identifiers iupac name n-triazolopyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide cas number1799329-72-8 ypubchem cid91810392chemspider58827646unii9nku4x5zkzchebichebi:133824 ychemical and physical dataformulac22h16fn7o3molar mass429.406 g·mol−13d model (jsmol)interactive image smiles n5ccccc5-c(cn1n4)cnc1nc4-c3cc(ccc3f)nc(=o)c2oc(c)nc2c inchi inchi=1s/c22h16fn7o2/c1-12-19(32-13(2)26-12)21(31)27-15-6-7-17(23)16(9-15)20-28-22-25-10-14(11-30(22)29-20)18-5-3-4-8-24-18/h3-11h,1-2h3,(h,27,31)key:wxzfcgryvwyytg-uhfffaoysa-n